MD Magazine August/ RNA Assessment Predicts Hepatitis C Relapse Two Weeks into Treatment

The MD Magazine Hepatitis C condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Here is a list of the latest headlines for August starting with todays update.

RNA Assessment Predicts Hepatitis C Relapse Two Weeks into Treatment
Aug 31, 2016   |   Caitlyn Fitzpatrick
Published in the Journal of Hepatology, the results showed that hepatitis C RNA levels in people with HCV genotype 3 who achieved sustained virologic response (SVR) were significantly lower during the first four weeks of SOF/RBV treatment than the levels observed in those who ended up relapsing.

Continue reading..

Exploring Treatment Failure Among Hepatitis C Patients
Although direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV), a small fraction of patients still experience treatment failure

Studying Faldaprevir and Deleobuvir Use in NS3/4A and NS5B Amino-acid Variants of Hepatitis C
Faldaprevir and deleobuvir resistance-associated variants (RAVs) are more common among virologic failures than at baseline in patients with treatment emergent NS3/4A and NS5B amino-acid variants of hepatitis C virus (HCV), according to the results of a recent study. Published on the website PLOSOne, the study was conducted by Kristi Berger, PhD, of Boehringer Ingelheim Pharmaceuticals, in Ridgefield Connecticut, and colleagues.

Even Light Drinking Spikes Cancer Risk in Hepatitis C-Related Cirrhosis

Aug 29, 2016 | ARTICLES | Caitlyn Fitzpatrick
It’s no secret that excessive alcohol consumption is dangerous to the liver; that’s exactly why patients with hepatitis C are advised to steer clear of it.

Interferon Combo Regimen for HCV GT2,3?
Aug 22, 2016 | ARTICLES | Dava Stewart
Despite the arrival of direct acting antivirals, there are limit options for patients with genotypes 2 and 3 of HCV infection. A drug combo using interferon appears to work, a study finds.

Study Looks at Barriers to Hepatitis C Treatment
Aug 19, 2016 | ARTICLES | Catherine Kolonko
Beyond high cost, people with hepatitis C face several barriers to treatment, and those arise from various sources. Doctors, Medicaid, private health insurance companies, and intravenous drug use can all be obstacles, according to a university study out of Massachusetts that examined treatment approvals for two new drugs.

Are Pan-Genotypics a Panacea for HCV?
Aug 18, 2016 | ARTICLES | Kenneth Bender
The list of effective drugs for the once incurable illness of hepatitis C infection keeps growing. But some physicians are frustrated. Here's why.

Comprehensive New Database an “Efficient and Helpful Tool” for Accessing HCV Research
Aug 16, 2016 | ARTICLES | Dava Stewart
“Each entry contains contextual information pertaining to the entry such as the HCV genotypic background and links to the original publication,” say the authors.

How Did Kids in Princeton Get HCV?
Aug 16, 2016 | ARTICLES | Gale Scott
The news that physicians in Princeton, NJ were confronting an outbreak of hepatitis C in young people who were also using heroin shocked this affluent, mostly white community. Ronald Nahass, MD, talks about how it occurred and what needs to happen next.

Study Explores Marijuana Use and Fibrosis in Women with HIV and Hepatitis C
Aug 12, 2016 | ARTICLES | Catherine Kolonko
A study in women coinfected with hepatitis C and HIV found that use of marijuana was not associated with progression to advanced liver fibrosis.

Traditional Chinese Medicine Kuan-Sin-Yin Found to Improve Liver Function in Hepatitis C Patients
Aug 09, 2016 | ARTICLES | Dava Stewart
In study, GPT and GOT levels significantly decreased in the Kuan Sin Yin group as compared to the placebo group, by 29.7% and 24.4% respectively.